Patent intelligence · US
US 11529381
Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
Patent details — US 11529381
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 20, 2022
- Expiration
- Dec 15, 2042
- Applicant
- PrecisionBiotics Group Limited
- Claims
- 9
- CPC classes
- A61K, A61K35/745, A61K9/0043, A61P
Quick answer
US 11529381 (Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection) is held by PrecisionBiotics Group Limited. Status: granted. Granted Dec 20, 2022. Expires Dec 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PrecisionBiotics Group Limited
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K35/745, A61K9/0043, A61P, A61P11/00, A61P11/06
More from PrecisionBiotics Group Limited
Related pharmaceutical patents in our USPTO index.
-
US 12419920
Bifidobacterium longum NCIMB 41676
granted -
US 12410418
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted -
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12232492
Disinfection of bacteriophages products using supercritical carbon dioxide
granted -
US 12233135
Therapeutic constructs for treating cancer
granted -
US 12180463
Lactobacillus reuteri
granted
Frequently asked questions
What is US patent 11529381?
US 11529381 (Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection) is held by PrecisionBiotics Group Limited. Status: granted. Granted Dec 20, 2022. Expires Dec 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11529381?
PrecisionBiotics Group Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.
When does US 11529381 expire?
Our index shows an expiration date of Dec 15, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.